NCT00352300 - Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

July 31, 2010

Conditions

Fallopian Tube CarcinomaInfectious DisorderNeutropeniaOvarian CarcinosarcomaPrimary Peritoneal CarcinomaStage III Ovarian CancerStage IV Ovarian Cancer

Interventions

PROCEDURE

Adjuvant Therapy

DRUG

Carboplatin

Given IV

DRUG

Paclitaxel

Given IV

BIOLOGICAL

Pegfilgrastim

Given IV

Trial Locations (11)

10016

New York University Langone Medical Center, New York

43210

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus

43214

Riverside Methodist Hospital, Columbus

44060

Lake University Ireland Cancer Center, Mentor

52242

University of Iowa Hospitals and Clinics, Iowa City

74104

Cancer Care Associates-Midtown, Tulsa

92868

University of California Medical Center At Irvine-Orange Campus, Orange

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

98195

University of Washington Medical Center, Seattle

08103

Cooper Hospital University Medical Center, Camden

02905

Women and Infants Hospital, Providence

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Gynecologic Oncology Group

NETWORK